Sparing the gut: COX-2 inhibitors herald a new era for treatment of horses with surgical colic.
Authors: Ziegler A L, Blikslager A T
Journal: Equine veterinary education
Summary
# Editorial Summary: COX-2 Inhibitors in Equine Surgical Colic Management Whilst flunixin meglumine has dominated colic pain management for decades, its non-selective inhibition of both COX-1 and COX-2 enzymes carries significant risks to renal and gastrointestinal function—precisely the systems already compromised during severe colic cases. Ziegler and Blikslager examine the emerging evidence supporting selective COX-2 inhibitors, particularly firocoxib, which target pain and inflammation whilst preserving the protective COX-1-mediated physiological functions essential for mucosal integrity and renal perfusion. The critical distinction between these drug classes addresses a longstanding clinical dilemma: conventional NSAIDs effectively reduce pain but may exacerbate the secondary gastrointestinal damage that often determines outcomes in surgical colics. By sparing COX-1-dependent processes, selective COX-2 inhibitors offer a more refined therapeutic approach that challenges the traditional reliance on flunixin, potentially improving survival rates and reducing post-operative complications in critical cases. For practitioners involved in colic management—whether in pre-referral pain control or post-surgical recovery—this evidence warrants reconsidering NSAID selection based on the underlying pathophysiology rather than habit, with firocoxib representing a more targeted alternative for horses with severe gastrointestinal disease.
Read the full abstract on PubMed
Practical Takeaways
- •Consider firocoxib as an alternative to flunixin for horses with surgical colic, particularly those with severe gastrointestinal disease, to reduce risk of NSAID-related complications
- •Understand the pharmacological difference: COX-2-selective drugs reduce inflammation and pain while preserving the protective gastrointestinal and renal functions provided by COX-1
- •Challenge established protocols—emerging evidence suggests firocoxib may offer superior safety margins in colic cases despite flunixin's entrenched use in equine practice
Key Findings
- •COX-2-selective NSAIDs like firocoxib can target pain and inflammation while preserving beneficial COX-1-driven renal and gastrointestinal functions
- •Flunixin meglumine, the traditional standard for colic pain management, carries high risk of adverse effects due to non-selective COX inhibition in critical cases
- •Firocoxib, a COX-2-selective NSAID labeled for equine use, may be preferable to flunixin in severe colic cases despite decades of clinical dogma favoring flunixin